Linezolid in Prophylaxis against Experimental Aortic Valve Endocarditis Due to Streptococcus oralis or Enterococcus faecalis
Open Access
- 1 February 2006
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (2) , 654-657
Abstract
There are no experimental studies regarding the prophylactic efficacy of linezolid against infective endocarditis. Nonbacterial thrombotic endocarditis of the aortic valve was induced in rabbits by the insertion of a polyethylene catheter. Twenty-four hours later, animals were randomly assigned to a control group, and groups receiving either ampicillin (two doses of 40 mg/kg of body weight each, given intravenously, 2 h apart) or linezolid (a single per os dose of 75 mg/kg). The first dose of ampicillin and the single dose of linezolid were administered 0.5 and 1 h, respectively, prior to the intravenous inoculation of ∼10 7 CFU of Streptococcus oralis or Enterococcus faecalis . Linezolid peak levels in rabbit serum were similar to the peak serum levels in humans following a 600-mg oral dose of linezolid. Linezolid prevented endocarditis in 87% of S. oralis -challenged rabbits ( P < 0.001 versus controls; P = 0.026 versus ampicillin). In rabbits challenged with E. faecalis , linezolid prevented endocarditis in 73% ( P = 0.003 versus controls; P = 0.049 versus ampicillin). Ampicillin prevented endocarditis due to S. oralis or due to E. faecalis in 47% ( P = 0.005 versus controls) and in 30% ( P = not significant versus controls) of the challenged animals, respectively. In conclusion, linezolid was effective as prophylaxis against endocarditis caused by a strain of S. oralis and to a lesser degree against that caused by a strain of E. faecalis . Its prophylactic efficacy was superior to that of ampicillin.Keywords
This publication has 26 references indexed in Scilit:
- Surveillance of linezolid resistance in Germany, 2001–2002Clinical Microbiology and Infection, 2005
- Efficacy of Linezolid Alone or in Combination with Vancomycin for Treatment of Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2003
- Prophylactic efficacy of linezolid alone or combined with levofloxacin and vancomycin in a rat subcutaneous pouch model of graft infection caused by Staphylococcus epidermidis with intermediate resistance to glycopeptidesJournal of Antimicrobial Chemotherapy, 2003
- Efficacy of Linezolid plus Rifampin in an Experimental Model of Methicillin-Susceptible Staphylococcus aureus EndocarditisAntimicrobial Agents and Chemotherapy, 2003
- Efficacy of Linezolid in Treatment of Experimental Endocarditis Caused by Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2001
- Linezolid Therapy of Vancomycin-Resistant Enterococcus faecium Experimental EndocarditisAntimicrobial Agents and Chemotherapy, 2001
- LinezolidDrugs, 2001
- Prevention of Bacterial Endocarditis: Recommendations by the American Heart AssociationClinical Infectious Diseases, 1997
- Chemoprophylactic efficacy against experimental endocarditis caused by beta-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activityAntimicrobial Agents and Chemotherapy, 1990
- Antibiotic prophylaxis of infective endocarditis Recommendations from the Endocarditis Working Party of the British Society for Antimicrobial ChemotherapyThe Lancet, 1990